Mirabegron (formerly YM-178, trade name Myrbetriq) is a drug for the treatment of overactive bladder. It was developed by Astellas Pharma and was approved in the United States in July 2012. Mirabegron activates the β3 adrenergic receptor in the detrusor muscle in the bladder, which leads to muscle relaxation and an increase in bladder capacity. (Source: http://en.wikipedia.org/wiki/Mirabegron)
MedKoo Cat#: 314233
Name: Mirabegron
CAS#: 223673-61-8
Chemical Formula: C21H24N4O2S
Exact Mass: 396.1620
Molecular Weight: 396.51
Elemental Analysis: C, 63.61; H, 6.10; N, 14.13; O, 8.07; S, 8.09
| Solvent | mg/mL | mM | comments | |
|---|---|---|---|---|
| Solubility | ||||
| DMF | 5.0 | 12.61 | ||
| DMSO | 55.9 | 141.01 | ||
| DMSO:PBS (pH 7.2) (1:6) | 0.1 | 0.25 | ||
| Ethanol | 6.3 | 15.91 |
The following data is based on the product molecular weight 396.51 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
